MannKind Corporation (MNKD) | Is It A One Trick Pony?

MannKind Stock NewsMannKind Corporation (NASDAQ: MNKD)

When you think about MannKind Corporation, what do you think about? If you’re like most traders and investors, chances are that you’re thinking about Afrezza; the company’s inhaled insulin that’s caused quite the debate. While I believe in Afrezza to the point where I think it could be the goose that laid the golden egg; I think investors, including myself have lost site of an important rule. Don’t put all of your eggs in one basket. The good news is that although we only really talk about one basket when it comes to MNKD, that’s not all they offer.

MannKind Outside Of Afrezza

There’s no doubt that Afrezza is an amazing product that will prove to be profitable in the long run, but what if something were to happen to it? Does MNKD have any other concepts in the pipeline? The answer is yes! The bottom line is that MannKind is not at all a one trick pony. The company is working on various treatments in various phases. Just to name a couple…

  • Technosphere Formula – MannKind’s Technosphere formula is used in Afrezza and helps to deliver insulin to the market. However, MannKind has openly stated that Technosphere is a product with applications that go far beyond the insulin delivery market. Many drugs that are currently injected may soon become inhaled drugs; which will allow for faster absorption and eliminate the need to take a shot! In my opinion, that’s absolutely amazing and has the potential to change everything in medicine.
  • Another Opportunity In Diabetes…GLP1 Agonists – MannKind is working on a drug class that’s should stimulate the pancreas to produce more insulin when blood sugar levels are too high. Currently, MNKD is in discussion with Sanofi about the opportunity.

Subscribe to The Prudent Speculator

What We’re Seeing From MNKD Today

After a decent climb in morning trading, the stock met resistance and started to move in the other direction. Currently (11:44), MNKD is trading at $4.29 per share with no gain so far today.

What We Can Expect To See Moving Forward

Moving forward, I still believe that this stock will grow. Afrezza is an amazing product that is met with quite a bit of feedback. Outside of Afrezza, MannKind has plenty more in its pipeline. Now, I’ll admit that management could use a bit of work. However, I do believe that this issue will iron itself out in the long run. With the incredible advancements the company has made in the world of diabetes, and medicine in itself, I believe that we will see long run growth.

What Do You Think?

Where do you think MNKD is headed and why? Let us know in the comments below!

Leave a Comment